Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT06058377 |
Title | Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer |
Recruitment | Recruiting |
Gender | female |
Phase | Phase III |
Variant Requirements | No |
Sponsors | National Cancer Institute (NCI) |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | USA |